PARP Inhibitor: 378 Clinical Trials, Page 10 of 38

Hide Studies Not Open or Pending


Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

Condition(s):ATM Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; BRIP1 Gene Mutation; CDK12 Gene Mutation; CHEK1 Gene Mutation; CHEK2 Gene Mutation; DNA Damage Response Gene Mutation; DNA Repair Gene Mutation; FANCA Gene Mutation; FANCD2 Gene Mutation; FANCL Gene Mutation; GEN1 Gene Mutation; NBN Gene Mutation; Prostate Carcinoma; RAD51 Gene Mutation; RAD51C Gene MutationLast Updated:April 8, 2021Recruiting


Veliparib and Temozolomide in Treating Patients With Acute Leukemia

Condition(s):Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL; Adult Acute Promyelocytic Leukemia With PML-RARA; Adult B Acute Lymphoblastic Leukemia; Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1; Adult T Acute Lymphoblastic Leukemia; Alkylating Agent-Related Acute Myeloid Leukemia; Chronic Myelomonocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid LeukemiaLast Updated:May 17, 2021Active, not recruiting

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.